Additionally, IL-18 has anti-inflammatory properties and may have a protective role against bone erosion by inhibiting osteoclast formation.[44] Additionally, a negative connection between IL-18bp and bisphosphonate-related osteonecrosis of the jaw was shown by de Barros Silva et al. One possible treatment target for osteonecrosis could be IL-18.[45]. The gene discussed is IL18; the disease is osteonecrosis.